Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Filter results: >>>>

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC1806	XL147	3	72	flat	flat	HCC1806 pilaralisib 0 3 72	8	3.185	Inf	1.02	0.000871	1.02	0.01	-2.12e-06	1.0	1.0	Inf	1.03	0.999	1.03	0.01	-0.000107	1.0	1.0
HCC1806	XL147	2	72	flat	flat	HCC1806 pilaralisib 0 2 72	8	2.817	Inf	1.02	0.000975	1.02	0.01	-4.46e-06	1.0	1.0	Inf	1.03	0.999	1.03	0.01	-0.000109	1.0	1.0
HCC1806	XL147	1	72	flat	flat	HCC1806 pilaralisib 0 1 72	8	2.732	Inf	1.02	0.00101	1.02	0.01	-4.53e-06	1.0	1.0	Inf	1.03	0.999	1.03	0.01	-0.000107	1.0	1.0
BT-20	Sirolimus	1	72	flat	flat	BT20 rapamycin 0 1 72	8	2.100	Inf	0.568	0.431	0.568	0.01	-9.89	1.0	0.568	Inf	0.6	0.601	0.6	0.01	-13.0	1.0	0.6
BT-20	Sirolimus	2	72	flat	flat	BT20 rapamycin 0 2 72	8	1.952	Inf	0.421	0.579	0.421	0.01	NA	NA	0.421	Inf	0.513	0.513	0.513	0.01	NA	NA	0.513
BT-20	Everolimus	2	72	flat	flat	BT20 everolimus 0 2 72	8	1.785	Inf	0.426	0.574	0.426	0.01	NA	NA	0.426	Inf	0.547	0.547	0.547	0.01	NA	NA	0.547
BT-20	Sirolimus	3	72	flat	flat	BT20 rapamycin 0 3 72	8	2.661	Inf	0.54	0.46	0.54	0.01	NA	NA	0.54	Inf	0.499	0.499	0.499	0.01	NA	NA	0.499